TABLE 2.
Effects of LY354740, mGlu2 receptor PAMs, mGlu2/3 receptor antagonists, and ketamine on MDD clinical trials, preclinical antidepressant screens, GAD clinical trials, and preclinical anxiolytic drug screens (see Supplemental Table 1 for this table with literature references)
| LY354740 (mGlu2/3 Agonist) | mGlu2 Receptor PAMs | mGlu2/3 Receptor Antagonists | Ketamine or Esketamine | |
|---|---|---|---|---|
| MDD clinical trials | not tested | Negative | Negative | POSITIVE |
| DRL 72-s behavior | Negative | Positive | Negative | Positive |
| Forced swim test | Negative | Positive | Positive | Positive |
| Tail suspension test | Negative | not tested | Positive | Positive |
| Olfactory bulbectomy | not tested | not tested | Positive | Positive |
| GAD clinical trials | POSITIVE | not tested | not tested | not tested |
| Elevated plus maze | Positive | Positive | Negative | Positive/negative |
| Stress-induced hyperthermia | Positive | Positive | Positive/negative | not tested |
| Lactate-induced panic | Positive | Positive | not tested | not tested |
| Fear-potentiated startle | Positive | Positive | Positive/negative | Positive/negative |